Sleep Loss Exacerbates Fatigue, Depression, and Pain in Rheumatoid Arthritis

Michael R. Irwin, MD1; Richard Olmstead, PhD1; Carmen Carrillo, MA, MHS1; Nina Sadeghi, BA1; John D. FitzGerald, MD, PhD2; Veena K. Ranganath, MD, MS2; Perry M. Nicassio, PhD1

Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience and Department of Psychiatry and Biobehavioral Sciences and Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

Study Objectives: Disturbances of sleep are hypothesized to contribute to pain. However, experimental data are limited to healthy pain-free individuals. This study evaluated the effect of sleep loss during part of the night on daytime mood symptoms and pain perceptions in patients with rheumatoid arthritis in comparison with control subjects.

Design: A between-groups laboratory study with assessment of mood symptoms and pain perception before and after partial night sleep deprivation (PSD; awake 23:00 hr to 03:00 hr).

Setting: General clinical research center.

Participants: Patients with rheumatoid arthritis (n = 27) and volunteer comparison control subjects (n = 27).

Measurements: Subjective reports of sleep, mood symptoms and pain, polysomnographic assessment of sleep continuity, and subjective and objective assessment of rheumatoid arthritis-specific joint pain.

Results: PSD induced differential increases in self-reported fatigue (P < 0.09), depression (P < 0.04), anxiety (P < 0.04), and pain (P < 0.01) in patients with rheumatoid arthritis compared with responses in control subjects, in whom differential increases of self-reported pain were independent of changes in mood symptoms, subjective sleep quality, and objective measures of sleep fragmentation. In the patients with rheumatoid arthritis, PSD also induced increases in disease-specific activity as indexed by self-reported pain severity (P < 0.01) and number of painful joints (P < 0.02) as well as clinician-rated joint counts (P < 0.03).

Conclusion: This study provides the first evidence of an exaggerated increase in symptoms of mood and pain in patients with rheumatoid arthritis after sleep loss, along with an activation of rheumatoid arthritis-related joint pain. Given the reciprocal relationship between sleep disturbances and pain, clinical management of pain in patients with rheumatoid arthritis should include an increased focus on the prevention and treatment of sleep disturbance in this clinical population.

Keywords: Sleep, sleep deprivation, fatigue, depression, anxiety, pain, joint pain, rheumatoid arthritis

Citation: Irwin MR; Olmstead R; Carrillo C; Sadeghi N; FitzGerald JD; Ranganath VK; Nicassio PM. Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis. SLEEP 2012;35(4):537-543.

INTRODUCTION

Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder that is characterized by joint pain and swelling.1 In addition, more than half of patients with RA report sleep disturbance (e.g., sleep fragmentation),2,3 a rate of prevalence that is typically shown loss of sleep during part of the night or sleep fragmentation. Furthermore, most have relied on selective sleep stage deprivation or on total sleep deprivation, which do not mimic the kind of sleep disturbance found in clinical populations such as patients with RA who are characterized by joint pain and swelling.1 In this study, an experimental model of partial night sleep deprivation (PSD), a ubiquitous sleep disruption pattern, was used to activate self-reported symptoms of pain and to determine whether sleep loss induces a differential increase in symptoms of self-reported pain in patients with RA in comparison with healthy control patients, taking into account subjective sleep quality and objective measures of sleep fragmentation. Additionally, sleep loss is hypothesized to contribute to disease activity and functional impairments in this clinical population; hence, joint pain was evaluated in patients with RA using guidelines created by the American College of Rheuma-
ology with assessment of both clinician-rated joint counts as well as subjective reports of pain using visual analog scales before and after PSD. Finally, given evidence that mood symptoms such as fatigue, depression, and anxiety occur with sleep disturbance and pain in RA patients, and that changes in mood symptoms might contribute to self-reported pain after sleep disturbance, the effect of sleep disturbance on mood symptoms and the contribution of these symptoms to pain perceptions in patients with RA in comparison with control subjects was also examined.

MATERIALS AND METHODS

Design Overview

This experimental study evaluated the effects of early night PSD (awake 23:00 to 03:00 hr) on self-reported measures of mood symptoms and pain between groups of patients with RA and control subjects, and on self-reported arthritis-specific and clinician-rated measures of joint pain in patients with RA. Participants were recruited through newspaper advertisements that stated the aim of the study as evaluating “sleep in rheumatoid arthritis patients [or healthy volunteers].” No additional information about the study hypothesis or about evaluation of pain perception was provided. Hence, participants were blinded to the study objectives and outcomes for self-rated measures of mood symptoms and pain perception.

Setting and Participants

Following approval by the UCLA Institutional Review Board, the study was conducted at the UCLA General Clinical Research Center (GCRC). The subjects included 27 patients with RA and 27 volunteer comparison control subjects. After a telephone screening, prospective patients with RA were referred to the UCLA Division of Rheumatology where study rheumatologists (JDF, VKR) confirmed the diagnosis of RA by conducting diagnostic evaluations that included review of medical records, completion of a medical history, and assessment of tender and swollen joints and disease activity. A structured comprehensive joint count assessment was completed with scoring of the number of joints that were tender and/or swollen. Sixty joints were evaluated on a scale from 0 (none) to 3 (severe) to indicate the extent of pain and swelling.

Eligible patients with RA were age 18 yr or older; met the 1987 American College of Rheumatology revised criteria for RA; were stable on a disease-modifying drug regimen for 3 mo prior to study entry; had a stable disease course for 3 mo; and did not have serious co-morbid medical conditions such as diabetes, congestive heart failure, renal failure, or cancer. Use of the following types of medication in the previous 2 mo was obtained for each patient with RA: analgesics/nonsteroidal anti-inflammatory drugs (NSAIDs); biologic agents; and disease-modifying antirheumatic drugs (DMARDs). Comparison control subjects also underwent a medical interview and physical examination by a staff physician; none had a history of an inflammatory disorder, cancer, or chronic or active infections. All participants had reference range results from screening laboratory tests (complete white blood cell count, metabolic panel) and for women a negative pregnancy test. Two-week sleep diaries confirmed that participants regularly slept between 22:30 and 07:30 prior to study entry; none were using sedative-hypnotic medications for sleep.

Procedures

After completion of screening and eligibility assessments, subjects spent 4 nights in the GCRC: adaptation, baseline, PSD, and recovery. The adaptation night served to acclimate subjects to the recording environment and to screen for sleep apnea (> 15 desaturation events per hour) and/or nocturnal myoclonus (> 10 movement-related, 3-sec arousals per hour); subjects with sleep apnea and/or nocturnal myoclonus were excluded. During baseline and recovery nights, uninterrupted sleep occurred between 23:00 and 07:00 hr, whereas during early-night PSD, subjects were awake between 23:00 and 03:00 hr, with sleep occurring between 03:00 and 07:00 hr. Throughout the night, polysonmography was performed with ambient light less than 50 lux. Objective measures of sleep continuity at baseline and during the sleep interval (i.e., after PSD and prior to the morning assessment) were obtained by polysomnography; a separate report will more comprehensively examine RA-specific clinical factors associated with polysomnographic sleep at baseline and in response to PSD in patients with RA compared with control subjects. During the days after baseline and PSD nights, measures of mood symptoms and pain perception were repeatedly obtained. In the patients with RA only, clinician-rated joint counts were measured at 08:00 hr after baseline, PSD, and recovery nights. Patients were monitored by GCRC nursing staff with routine checks every 15 min to prevent napping behavior.

Measures

Severity of sleep disturbance at baseline was evaluated by the Pittsburgh Sleep Quality Index (PSQI), a widely used, self-report questionnaire that measures sleep disturbances. Objective measures of sleep continuity (i.e., total sleep time, sleep latency, wake after sleep onset, sleep efficiency) were obtained by all-night polysomnography using methods previously reported. The Profile of Mood States evaluated changes in fatigue, depression, and anxiety. To evaluate changes in subjective pain perception, the McGill Pain Questionnaire (MPQ) was used; the MPQ provides a sum of the ranked values associated with adjectives depicting the severity of pain and shows good reliability (0.78) and also correlates moderately with physician assessment of disease activity ($r = 0.44$) and patient assessment of disease activity ($r = 0.68$) in patients with RA. In these patients, a 5-point visual analog scale was also used to estimate RA-specific disease activity (i.e., number of painful joints, overall pain severity), and the structured 60-joint count was also completed before and after PSD by the RA clinicians.

Data Analyses

Data were analyzed using SAS version 9.13 for Windows (SAS Institute, Inc., Cary, NC). Differences between the patients with RA and the control patients in demographic and clinical variables were tested by $t$-tests and chi-square tests. To determine the effects of PSD on mood symptoms and self-reported measures of pain in the patients with RA compared with control subjects, repeated-measures mixed-model analyses of variance (ANOVARs) were performed using a 2 (group: RA, control) × condition (baseline, PSD) × 5 (time: 08:00, 12:00, 16:00, 20:00, 02:00) × 2 (sleep deprivation: yes, no) design. Outliers were tested using Studentized residuals.
RESULTS

Demographic and Clinical Characteristics

Table 1 displays the demographic and clinical characteristics of the RA and control groups. The 2 groups were similar in terms of age, sex, education, income, employment status, marital status, and body mass index. There was a trend for the RA group to have more non-white subjects, although this difference was not significant. Patients with RA reported significantly greater sleep disturbance in comparison with control subjects, with mean PSQI scores indicating clinical sleep impairment. Patients with RA reported treatment with a combination of biologic agents, DMARDs, and NSAIDs to manage their symptoms. DMARDs were the most commonly used medication (55.6%), with the use of biologic agents (48.1%), steroids (14.8%), and NSAIDs (3.7%) also reported. Among the patients with RA, covarying for the use of these various medications as a block on all disease-specific outcomes did not alter the results.

Mood responses to PSD

PSD induced differential increases in self-reported fatigue, depression, and anxiety in the patients with RA in comparison with the control subjects. For fatigue, there were significant main effects for group (F(1,51.15) = 9.05, P < 0.005), condition (F(1,440.81) = 73.25, P < 0.001), and time (F(4,440.44) = 7.01, P < 0.001), with a trend for a group × condition interaction (F(1,440.81) = 2.96, P < 0.09) in which patients with RA reporting greater increases of fatigue after PSD than control subjects (Figure 1A). Likewise for self-reported depression, there were significant main effects for group (F(1,51.23) = 3.93, P = 0.05) and time (F(4,440.55) = 3.51, P < 0.01), but not condition, with a group × time interaction (F(4,440.55) = 2.65, P < 0.04) in which patients with RA showed higher levels of depression immediately before (23:00 hr) and after PSD (08:00 hr) as compared with control subjects (P < 0.05) (Figure 1B). Finally, for self-reported anxiety, there were main effects for group (F(1,51.43) = 7.45, P < 0.01) and time (F(4,439.88) = 3.22, P < 0.02), with a group × condition × time interaction (F(4,439.87) = 2.62, P < 0.04), in which patients with RA showed higher levels of anxiety immediately before (23:00 hr) and after PSD (08:00, 12:00, 16:00) as compared with control subjects (P < 0.05) (Figure 1C).

Self-reported pain responses to PSD

For self-reported pain as indexed by the MPQ, patients with RA also showed an exaggerated response as compared with control subjects (Figure 2). There was an overall significant group effect (F(1,50.0) = 37.95, P < 0.001) with the RA group reporting more pain than the control group. There was an overall condition effect (F(1,426.6) = 13.66, P < 0.001), a marginal time effect (F(4,426.36) = 1.11, P = 0.06), and a significant group × condition × time interaction (F(4,426.4) = 3.04, P < 0.02). Specific comparisons demonstrated significant (P < 0.01) time effects for both groups at 08:00 immediately after PSD, with patients with RA having greater (P < 0.01) self-reported pain at 08:00 immediately after PSD in comparison with control subjects.

Given the differential changes of fatigue, depression, and anxiety in response to PSD between the RA and control groups, as well as evidence that these mood symptoms are associated with RA pain, we examined whether variations in self-reported mood were explanatory to changes in pain between the 2 groups. Using time-varying covariates, there were main effects for fatigue (F(4,417.58) = 10.07, P < 0.005) and depression (F(1,466.61) = 18.00, P < 0.001), but not anxiety. When all 3 covariates were used, the results for self-reported pain were largely maintained with a group × condition × time interaction (F(4,417.58) = 2.26, P < 0.06) compared with the original result (F(4,426.4) = 3.04, P < 0.02). Additional exploratory analyses tested whether these mood measures predicted pain values using within-time and lagged correlations; none of these correlations were significant (P > 0.1). Partial correlation analyses also failed to support the exploratory hypothesis that antecedent mood measures predicted subsequent pain.

Table 1—Demographic and clinical characteristics of comparison control patients and those with rheumatoid arthritis

<table>
<thead>
<tr>
<th>Variables</th>
<th>Comparison control (n = 27)</th>
<th>Rheumatoid arthritis (n = 27)</th>
<th>t</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>Mean 60.4 ± 10.2</td>
<td>Mean 59.9 ± 11.1</td>
<td>0.19</td>
<td>0.85</td>
</tr>
<tr>
<td>Educational level (yr)</td>
<td>16.1 ± 3.1</td>
<td>15.1 ± 5.1</td>
<td>1.17</td>
<td>0.25</td>
</tr>
<tr>
<td>Income ($k/yr)</td>
<td>66.1 ± 51.6</td>
<td>64.5 ± 48.9</td>
<td>0.13</td>
<td>0.90</td>
</tr>
<tr>
<td>BMI</td>
<td>25.4 ± 5.0</td>
<td>27.2 ± 4.6</td>
<td>1.31</td>
<td>0.20</td>
</tr>
<tr>
<td>PSQI</td>
<td>2.4 ± 2.0</td>
<td>7.6 ± 3.8</td>
<td>6.18</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>21 ± 7.9</td>
<td>24 ± 9.9</td>
<td>1.2</td>
<td>0.28</td>
</tr>
<tr>
<td>Minority (non-Euro-American)</td>
<td>9 ± 33</td>
<td>16 ± 59</td>
<td>3.7</td>
<td>0.06</td>
</tr>
<tr>
<td>Marital status (married/partner)</td>
<td>13 ± 48</td>
<td>12 ± 44</td>
<td>0.1</td>
<td>0.79</td>
</tr>
<tr>
<td>Employment status (employed)</td>
<td>13 ± 48</td>
<td>8 ± 30</td>
<td>1.9</td>
<td>0.16</td>
</tr>
</tbody>
</table>

BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; SD, standard deviation.
Baseline differences in PSQI scores were found between the 2 groups. Hence, differential change in self-reported pain was examined with PSQI scores included as a main effect covariate and as a component of a competing higher-order interaction term with condition and time. Whereas there was a main covariate effect of PSQI scores on self-reported pain ($F(1,47.95) = 6.39, P < 0.02$), inclusion of PSQI did not eliminate the main group effect ($F(1,47.91) = 12.98, P < 0.005$) nor the group $\times$ condition $\times$ time interaction ($F(1,430.84) = 2.65, P < 0.04$) for self-reported pain.

Given our findings that sleep loss increased pain perceptions, and that pain is associated with sleep disturbance (e.g., sleep fragmentation), we explored whether sleep fragmentation occurred in patients with RA versus control patients by obtaining polysomnographic measures of sleep continuity at baseline and during the sleep interval after PSD immediately prior to the morning assessment of pain responses. At baseline, patients with RA showed greater amounts of wake after sleep onset and poorer sleep efficiency at baseline in comparison with control patients (Table 2). However, in the immediate sleep interval after PSD, these 2 objective markers of sleep fragmentation were similar in the 2 groups. Measures of total sleep time and sleep latency were similar in the 2 groups before and after PSD (Table 2).

**RA-specific self-reported and objective pain responses to PSD**

PSD also induced increases in RA-specific disease activity as indexed by joint pain severity and self-reported number of painful joints as measured in the patients with RA only. For overall RA-related joint pain severity (Figure 3), there was both a significant effect for condition ($F(1,214.03) = 8.84, P < 0.005$) and a significant overall time effect ($F(4,214.04) = 7.69, P < 0.001$), but no condition $\times$ time interaction. Specific comparisons demonstrated that pain severity at 08:00 immediately after PSD was significantly greater than all other time points ($F(1,17) = 5.63, P < 0.03$). Likewise, for self-reported number of painful joints, there was a significant time effect ($F(2.5,58.3) = 4.09, P < 0.02$) and a nonsignificant trend for a condition $\times$ time interaction ($F(3.4,58.3) = 2.50, P < 0.07$), in which joint pain at 08:00 immediately after PSD was significantly greater than all other time points ($F(1,17) = 4.79, P < 0.05$) (Figure 4). Finally, for clinician-rated joint counts (Figure 5), planned comparisons showed increases in the morning after PSD as compared to baseline ($t(15) = 2.07, P < 0.03$) and recovery mornings ($t(9) = 1.96, P < 0.04$).

**DISCUSSION**

This study provides the first evidence of an exaggerated increase in symptoms of pain in patients with RA compared with control subjects after sleep loss. In the morning after PSD, self-reported pain symptoms were elevated in RA patients in comparison with control subjects. In addition, sleep loss activated RA-related joint pain as indicated by increases in the number of painful joints and the severity of associated joint pain. Moreover, clinician-rated painful and tender joints increased after this modest sleep loss in patients with RA. Finally, given that objective measures of sleep fragmentation were similar in the 2 groups during the sleep interval immediately after PSD, it appears that sleep loss, as opposed to sleep fragmentation, has a unique role in the differential induction of pain symptoms in patients with RA versus control subjects.
Sleep Deprivation and Pain in RA—Irwin et al

Decline in these patients. In addition, sleep disturbance is associated with an overnight increase in tenderness in the peripheral joints in patients with RA who are experiencing an acute flareup of symptoms. Hence, in the midst of recurrent nights of sleep loss, it is possible that repeated, transient elevations of RA-specific joint pain might lead to an exacerbation of RA symptomatology. Together these data support future efforts to prevent and treat sleep disturbance (e.g., improving sleep duration) in patients with RA as a means of potentially reducing pain.

Cognitive behavioral treatment (CBT) for insomnia has been found to be as effective as sedative hypnotic medications in the short- and long-term management of clinical insomnia, and there is some evidence that either CBT or pharmacotherapy for insomnia improves sleep and pain symptoms in various chronic pain populations. One trial reported improvements in sleep and morning stiffness with pharmacotherapy for insomnia (i.e., triazolam) in patients with RA.

Consistent with prior experimental findings in healthy volunteers, PSD also led to a modest increase in self-reported pain. One small study had previously found that PSD induced hyperalgesia in response to sleep loss do not appear to mediate increases in self-reported pain responses.

Although increases of self-reported pain were short-lasting, transient increases in symptoms of pain after sleep loss have implications of increased disease activity in patients with RA, as cross-sectional and prospective data suggest that sleep disturbance is a risk factor for the exacerbation of pain and functional

Table 2—Polysomnographic measures of sleep continuity at baseline and during the sleep interval after early night partial sleep deprivation in patients with rheumatoid arthritis and control patients

<table>
<thead>
<tr>
<th></th>
<th>Baseline night</th>
<th>PSD sleep interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Comparison control</td>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>Total sleep time (min)</td>
<td>Mean, SD</td>
<td>Mean, SD</td>
</tr>
<tr>
<td></td>
<td>392, 33</td>
<td>378, 34</td>
</tr>
<tr>
<td>Sleep latency (min)</td>
<td>25.2, 22.9</td>
<td>25.1, 18</td>
</tr>
<tr>
<td>Wake after sleep onset (min)</td>
<td>53.7, 30.1</td>
<td>73.3, 32.3</td>
</tr>
<tr>
<td>Sleep efficiency (%)</td>
<td>88.0, 6.6</td>
<td>83.8, 7.0</td>
</tr>
</tbody>
</table>

PSD, partial night sleep deprivation; SD, standard deviation.

Prior studies have found that mood symptoms including fatigue, depression, and anxiety are prominent in patients with RA. The current study confirms these observations and further demonstrates that sleep loss is associated with exaggerated increases of these mood symptoms, which is due either to the direct effects of sleep loss (e.g., fatigue) or to indirect effects related to the anticipation of sleep loss (e.g., anxiety) in patients with RA in comparison with control subjects. Importantly, whereas cross-sectional and longitudinal naturalistic studies report associations between symptoms of mood, sleep disturbance, and pain in patients with RA, the current findings indicate that the effect of sleep loss on pain symptoms is independent of changes in mood symptoms. Increases of mood symptoms in response to sleep loss do not appear to mediate increases in self-reported pain responses.
in healthy volunteers.\textsuperscript{12} However, Smith et al.\textsuperscript{14} reported that only sleep fragmentation, not restriction of sleep duration, was associated with increases in spontaneous pain in healthy women, finding that contrasts with our observations that differential increases in pain perceptions in the patients with RA versus control subjects are associated with sleep loss but not sleep fragmentation. Yet, when PSD is repeated for several nights (i.e., 12 nights at 4 hr of sleep per night) or the duration of sleep loss is prolonged (i.e., 1 or 2 nights), there is evidence of hyperalgesia,\textsuperscript{8,11,13} although not all studies have found that total sleep deprivation alters pain sensitivity.\textsuperscript{34} These varying findings, taken together with our observations in patients with RA, suggest that activation of pain can occur after sleep loss but this response is heterogeneous and/or more likely in certain populations, possibly due, for example, to a heightened signaling of the neurobiologic mechanisms (e.g., inflammation) that contribute to pain.

RA is characterized as an inflammatory disorder with evidence of activation of inflammatory signaling (i.e., activation of nuclear factor-κB, NF-κB) as well as increases in the localized, cellular, and systemic expression of inflammatory cytokines such as interleukin-6 (IL-6).\textsuperscript{35} Additionally, we have found that PSD induces increases in NF-κB signaling,\textsuperscript{36} which leads to the cellular and genomic expression of inflammatory markers,\textsuperscript{37} which is exaggerated in women.\textsuperscript{36-38} Other data show sex differences in sympathetic nervous system upregulation of IL-6 production,\textsuperscript{39} and we have found that PSD induces increases in sympathetic activity.\textsuperscript{40} Hence, it is possible that sleep loss-induced increases in proinflammatory cytokine activity contribute to pain responses after sleep loss, as animal studies have shown that exogenous doses of IL-6 or inflammatory challenges (e.g., endotoxin) induce states of hyperalgesia, in which increases in inflammation are thought to be linked to the development of chronic pain.\textsuperscript{41} Future studies are under way to understand whether differences in inflammatory signaling drive the exaggerated pain profile in patients with RA versus controls patients after following sleep loss. Haack et al.\textsuperscript{42} have found that prolonged partial sleep restriction elevated circulating levels of IL-6 in association with pain ratings in healthy volunteers.\textsuperscript{42}

Interpretation of these findings requires consideration of several limitations. First, the experimental sleep deprivation used in this study, like all other sleep deprivation studies that target sleep continuity or duration, was single blinded. Hence, it is possible that the observed effects might be partially attributable to subject expectancies. However, it is unlikely that expectancy effects contributed to differences in response between the 2 groups, who were given similar information about the study. Moreover, such bias would not likely have contributed to the changes in objective, clinician-rated joint counts; the clinician(s) were blinded to the experimental condition. Second, the study relied on reports of spontaneous pain and/or RA-related joint pain by self-report and clinician ratings. Laboratory assessments of pain such as mechanical or thermal pain sensitivity are not used in studies of RA. Rather, the assessments used here followed clinical guidelines for the evaluation of joint pain in patients with RA, with implications for disease activity in this patient population. Third, the sample population was composed mainly of female subjects consistent with the increased prevalence of RA in females. Hence, conclusions about the generalizability of these findings to males cannot be made. Finally, it should also be noted that although an attempt was made to control for baseline differences in PSQI scores, the combination of modest sample size, and limited power for testing interactions with continuous variables, this variable may be more important than the current results suggest. Indeed, additional analyses are under way to examine the associations between subjective and objective measures sleep disturbance and pain in patients with RA, and to test whether differences in homeostatic regulation of sleep, as we found in alcohol-dependent populations,\textsuperscript{42} contribute to exaggerated pain responses after PSD in patients with RA.

This study addresses two major clinical issues in RA patients: sleep disturbance and joint pain. Although it is widely thought that sleep disturbance is a consequence of joint pain in patients with RA, these experimental observations support an alternative hypothesis that sleep loss leads to increases in joint pain in patients with RA. This profile of sleep loss during part of the night,
ubiquitous in those with RA as well as other patients with chronic pain, may result in a vicious cycle in which sleep disturbance activates clinical symptoms of pain, which then contributes to further sleep loss. Importantly, these findings have the potential to redirect the clinical management of pain in patients with RA to include an increased focus on sleep and the prevention and treatment of sleep disturbance in this clinical population.

ACKNOWLEDGMENTS
This work was supported by a National Institute of Health grant # R01 HL 079955 and in part by grants R01-AG 18367; T32-MH18399, R01-AG 026364, R01-AG 034588, R01-CA 10014152, M01-RR00865, P30-AG028748, General Clinical Research Centers Program, the UCLA Cousins Center at the Semel Institute for Neurosciences, and the UCLA Older Americans Independence Center Inflammatory Biology Core.

DISCLOSURE STATEMENT
This was not an industry supported study. Drs. Irwin, Olmstead, FitzGerald, Ranganath, and Nicassio have received research support from the National Institutes of Health. The other authors have indicated no financial conflicts of interest.

REFERENCES

SLEEP, Vol. 35, No. 4, 2012